New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 2, 2000, Pages 164-169

  Barnette, Mary S ^a   Underwood, David C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; AROFYLLINE; CILOMILAST; CYCLIC AMP; CYCLIC GMP; PHOSPHODIESTERASE INHIBITOR; ROFLUMILAST; ROLIPRAM; UNCLASSIFIED DRUG; V 1129A;

ASTHMA; BRONCHODILATATION; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; REVIEW;

EID: 0033818504     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200003000-00014     Document Type: Review

References (65)

1. Phosphodiesterase isozymes molecular targets for novel II anti-asthma agents
2. The multienzyme PDE4 cyclic ladenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions
3. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys
4. Hyperpermeability of pulmonary endothelial monolayer: Protective role of phosphodiesterase isoenzymes 3 and 4
5. Effects of phosphodiesterase inhibitors and salbutamol on microvascular leakage in guinea-pig trachea
6. Phosphodiesterase expression in human epithelial cells
7. Identification and function of cyclic nucleotide Iphosphodiesterase isoenzymes in airway epithelial cells
8. Effects of selective and non-selective phosphodiesterase inhibitors on tracheal mucus secretion in the rat
9. Inflammatory and structural changes in the small airways in bronchial asthma
10. + T lymphocytes with FEV
11. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease
12. Phosphodiesterase (PDE) 4 inhibitors: Anti-inflammatory drugs of the future
13. Phosphodiesterase 4: Biological underpinnings for the design of improved inhibitors
14. Effects of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: Synergism with prostanoids and salbutamol
15. Inhibitors of phosphodiesterse type 4 enzymes inhibit RANTES release by cytokine treated human airway smooth muscle cells
16. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor
17. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram
18. Suppression of TNF-a expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram
19. The phosphodiesterase inhibitors pentoxifylline and rotipram prevent diabetes in NOD mice
20. Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs
21. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys
22. Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits
23. Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration
24. PDE4 inhibition and a corticosteroid in chronically antigen exposed conscious guinea-pigs
25. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor
26. The effects of zardaverine, an inhibitor of phosphodieserase isoenzymes III and IV, on endotoxin-induced airway changes in rats
27. Effects of isoenzyme selective phosphodiestserase inhibitors on bacterial lipopolysaccharide-induced bronchial hyper-reactivity in guinea pigs
28. Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs
29. 1998 Effect of selective Iphosphodiesterase inhibitors on citric acid-induced cough in sensitized and non-sensitized guinea pigs
30. Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitors
31. Possible rote of cAMP, cGMP and [Cai] during NANC relaxation the cat airway smooth muscle
32. Potentiation of nonadrenergic noncholinergic relaxation of human isolated bronchus by selective inhibitors of phosphodiesterase isozymes
33. Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: Relationship to elevated cAMP levels
34. VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle
35. Antiproliferative effects of prostaglandin E2 in cultured guinea pig tracheal smooth muscle cells
36. Adrenergic receptor-mediated regulation of cultured rabbit airway smooth muscle cell proliferation
37. Effect of Cl-930 [3-(2H)-pyridazinone-4,5-dihydro-6-[4-(1H-imidazolyl) phenyl]-5-methyl monohydrochloride] and rolipram on human coronary artery smooth muscle cell proliferation
38. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells
39. 1999 Modulation of human airway smooth muscle proliferation by type 3 phosphodiesterase inhibition
40. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors
41. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease, state-of-the-art: Parts one and two
42. The pulmonary circulation: Remodeling in growth and disease
43. Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries
44. Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: Differences between early and established pulmonary hypertension
45. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital head disease
46. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension
47. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses
48. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message
49. The effects of a novel lorally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects
50. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterse 4 inhibitor: In vitro anti-inflammatory actions
51. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor a and interleukin-4 production in vivo
52. Antiasthmatic activity of the second generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig
53. SB 207499 (Ariflo), a second-generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor attenuates exercise induced bronchoconstriction in patients with asthma
54. The safety and tolerability of Ariflo (SB 207499), a novel and selective phosphodiesterase 4 inhibitor, in healthy male volunteers
55. Ariflo(TM) improves pulmonary function in patients with asthma: Results of a study in patients taking inhaled corticosteroids
56. Ariflo(TM) (SB 207499), a second generation, oral PDE4 inhibitor improves quality of life in patients with COPD
57. The efficacy of Ariflo(TM) (SB 207499), a second generation, oral PDE4 inhibitor, in patients With COPD
58. Oral administration of the phosphodiesterase (PDE)4 inhibitor, V1129A inhibits ex vivo agonist induced cell activation
59. Pharmacodynamic-pharmacokinetic (PD/PK) profile of the phosphodiesterase (PDE) 4 inhibitor, V1129A, in human volunteers
60. 1997 Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases
61. Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities
62. Differential distribution of mRNA encoding cAMP-specific phosphodiesterase isoforms in the rat brain
63. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement and affect
64. 1,4,-cyclohexanecarboxylates potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma
65. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B